Angle PLC Announces Notice of Results

Arizona Tribune - Angle PLC Announces Notice of Results

Angle PLC Announces Notice of Results

Notice of Preliminary Results and Webcast

Text size:

GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its preliminary results for the year ended 31 December 2024 on Wednesday 28 May 2025.

A meeting for analysts will be held at 11:00 am BST on Wednesday 28 May 2025 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD.

A live webcast of the analyst meeting can be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/, with Q&A participation reserved for analysts only. Please register in advance and log on to the webcast approximately 5 minutes before 11:00 am on the day of the results. A recording of the webcast will be made available on ANGLE's website following the results meeting.

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Sam Purewal Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

W.Stewart--AT

RBGPF	0%	61.3	$
CMSC	-0.2%	22.065	$
NGG	1.52%	82.83	$
VOD	-1.74%	13.81	$
RELX	-0.19%	31.15	$
RYCEF	-0.89%	18	$
BTI	1.06%	61.39	$
RIO	-1.65%	94.03	$
BP	-3.88%	37.86	$
GSK	-1.92%	51.09	$
CMSD	0.27%	22.02	$
JRI	-0.48%	12.57	$
BCE	0.69%	23.2	$
BCC	7.55%	77.66	$
AZN	1.09%	183.02	$

Arizona Tribune - Angle PLC Announces Notice of Results

Angle PLC Announces Notice of Results

Featured

Mothers search, men weep amid debris of Venezuela quakes

Venezuela declares state of emergency after powerful twin quakes

Bulgaria's milk farmers falter in former yogurt empire

Twin earthquakes in Venezuela destroy buildings, sow panic